"What doesn’t kill you, makes you stronger," said German philosopher Friedrich Nietzsche. COVID-19 might be a lesson in not ignoring an imminent threat, but it has also led to unprecedented process improvements and collaborative mindsets that will help the industry deal with the next pandemic when it hits.
Novartis, Takeda See Industry Better Prepared For Next Pandemic
Repurposing Drugs Not Ideal
Novartis and Takeda’s R&D efforts saw an impact from the COVID-19 pandemic, but both Lutz Hegemann and Andrew Plump believe that when the next pandemic hits, the industry and regulators will be better prepared for it.
More from COVID-19
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.